Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABCD-NK: Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AML
NCT06158828Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2024
- Primary completion
- Sep 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of cytokine-induced memory-like natural killer cells in acute myeloid leukemia (AML) (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Safety of patients being administered donor-derived ML NK cells and Feasibility of manufacturing and administering donor-derived ML NK cells. Started Nov 2024; status: recruiting.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06158828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158828.